Please login to the form below

Not currently logged in
Email:
Password:

Gilead's HIV drug Genvoya cleared in EU

First TAF-based regimen to be approved in the US and EU
Gilead

Gilead has received approval from the European Commission for its HIV drug Genvoya. 

The approval comes on the back of data from two ongoing phase III studies involving 1,733 treatment-naïve adult patients.

The drug met its primary endpoint of non-inferiority to Gilead's own HIV therapy Stribild (elitegravir, cobicstat, emtricitabine and TDF).

Norbert Bischofberger, executive vice president of research and development and chief scientific officer at Gilead, said: “For more than 25 years, Gilead has continually worked to develop new treatments to improve the management of HIV.

“Genvoya, along with other investigational products in our TAF-based portfolio, have the potential to deliver long-term health benefits to people living with HIV across Europe and around the world.”

Genvoya (elvitegravir/cobicstat/emitricitabine/tenofovir alafenamide) is the first TAF-based regimen to win approval in both the US and EU.

TAF is a novel targeted prodrug of tenofovir that has shown high antiviral activity similar to a dose less than one-tenth that of Gilead's Viread (tenofovir disoproxil fumarate, TDF).

However, because TAF enters cells more efficiently than TDF, it can be given at a lower dose and there is 91% less tenofovir in the bloodstream.

Additional Genvoya has also shown an improvement in renal and bone safety versus TDF therapy, which is crucial given that HIV patients are at increased risk from age and treatment related comorbidities such as low bone mineral density and renal impairment.

Article by
Nikhil Patel

25th November 2015

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....